Premium
Double‐conditioning regimen consisting of high‐dose thiotepa and melphalan with autologous stem cell rescue for high‐risk pediatric solid tumors: A second report
Author(s) -
Okada Keiko,
Yamasaki Kai,
Nitani Chika,
Fujisaki Hiroyuki,
Osugi Yuko,
Hara Junichi
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27953
Subject(s) - thiotepa , medicine , mucositis , melphalan , regimen , toxicity , gastroenterology , renal function , chemotherapy , surgery , refractory (planetary science) , cyclophosphamide , physics , astrobiology
Background Pediatric patients with high‐risk, relapsed, or refractory solid tumors have a poor prognosis. We have previously reported a dose‐finding experience of high‐dose chemotherapy consisting of thiotepa and melphalan (“double‐conditioning regimen”). Using doses derived from that study, we have treated patients since 2005. We now report a retrospective review of patients treated by this fixed dose. Procedure We reviewed 50 patients (median 4 years; range 0–15 years) with high‐risk or relapsed/refractory solid tumors treated by this dose‐fixed, double‐conditioning regimen from April 2005 to May 2014. Doses were thiotepa 800 mg/m 2 and melphalan 280 mg/m 2 for children ≥2 years of age, and 32 mg/kg and 6 mg/kg, respectively, for children <2 years of age. Further, doses were reduced according to creatinine clearance with poor renal function. Results Nonhematological toxicity was mainly gastrointestinal—grade 3 mucositis ( n = 41) and grade 3–4 diarrhea ( n = 10). Neurological, renal, and endothelial cell toxicity and sinusoidal obstruction syndrome were not observed. There were two toxic deaths (interstitial viral pneumonia). This regimen demonstrated antitumor activity against several types of tumors. Although the frequency of gastrointestinal toxicity was high, other severe toxicity was not observed. Conclusions Our double‐conditioning regimen was very well tolerated and demonstrated antitumor activity. We are moving forward with multi‐institutional trials now.